Liver transplantation and autoimmune hepatitis

Access this Article

Search this Article

Author(s)

    • Sugawara Yasuhiko
    • Artificial Organ and Transplantation Division, Department of Surgery, Graduate School of Medicine, The University of Tokyo
    • Kokudo Norihiro
    • Artificial Organ and Transplantation Division, Department of Surgery, Graduate School of Medicine, The University of Tokyo

Abstract

Liver Transplantation (LT) is an effective treatment for patients with end-stage liver disease including autoimmune hepatitis (AIH). Indication for LT for AIH does not differ basically from other liver diseases including both acute and chronic types of disease progression, although it is reported to be an infrequent indication for LT worldwide due to the therapeutic advances of immunosuppression. The outcome following LT is feasible, with current patient and graft survival exceeding 75% at 5 years. Recurrent and <i>de-novo</i> AIH posttranslant has also been reported; and this seems to have important clinical implications because its management differs from the standard treatment for allograft rejection. In this review, we discuss the characteristics of AIH, focusing on the indication for LT and issues raised following LT.

Journal

  • Intractable & Rare Diseases Research

    Intractable & Rare Diseases Research 4(1), 33-38, 2015

    International Research and Cooperation Association for Bio & Socio-Sciences Advancement

Codes

Page Top